Skip to main content
Douglas Tremblay, MD, Hematology, New York, NY

Douglas Allen Tremblay MD


Physician

Join to View Full Profile
  • 10 E 102nd StNew York, NY 10029

  • Phone+1 212-241-6756

Dr. Tremblay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Icahn School of Medicine at Mount Sinai (Bronx)
    Icahn School of Medicine at Mount Sinai (Bronx)Residency, Internal Medicine, 2014 - 2017
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 2014

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2015 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Inductee Alpha Omega Alpha Honor Medical Society

Publications & Presentations

PubMed

Abstracts/Posters

  • Impact of Primary Antibacterial Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients
    Douglas Tremblay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
    Douglas Tremblay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis
    Douglas Tremblay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Utility of Thrombophilia Testing in Portal Vein Thrombosis in a Large Single Institutional Cohort 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • FDA Approves Momelotinib (Ojjaara) for Myelofibrosis Patients with Anemia
    FDA Approves Momelotinib (Ojjaara) for Myelofibrosis Patients with AnemiaSeptember 20th, 2023

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: